Cosentyx Injection

Indicated for, moderate-to-severe plaque psoriasis, in patients who are candidates for systemic therapy or phototherapy, indication includes, treatment for moderate-to-severe scalp psoriasis, active psoriatic arthritis, active ankylosing spondylitis

Powd for inj: Reconstitute 150 mg vial w/ 1 mL sterile water for inj to make a 150 mg/mL soln.

Subcutaneous Plaque psoriasis Adult: 300 mg every week for 5 doses, followed by 300 mg every month. Each 300 mg dose is given as 2 injections of 150 mg. Review treatment if no response within 16 weeks of initial dose. Psoriatic arthritis Adult: 150 mg every week for 5 doses, followed by 150 mg every month, may increase to 300 mg if response is inadequate. Coexistent moderate to severe plaque psoriasis or anti-TNF? inadequate responders: 300 mg every week for 5 doses, followed by 300 mg every month. Review treatment if there is no response after 16 weeks. Ankylosing spondylitis Adult: 150 mg once weekly for 5 weeks, then once monthly thereafter. Review treatment if there is no response after 16 weeks.

Serious infections (e.g. active TB, hepatitis B, sepsis). Admin of live vaccines.

Secukinumab is a recombinant fully human IgG1/K monoclonal antibody that selectively binds to interleukin-17A (IL-17A), a cytokine involved in normal inflammatory and immune responses, thus inhibiting the release of proinflammatory cytokines, chemokines, and mediators of tissue damage.

Patient w/ history of recurrent or chronic infection, inflammatory bowel disease (e.g. Crohn’s disease). Pregnancy and lactation.

>10% Infections (28.7%) Nasopharyngitis (11.4-12.3%) 1-10% Diarrhea (2.6-4.1%) URT infection (2.5-3.2%) Rhinitis (1.4%) Oral herpes (0.1-1.3%) Pharyngitis (1-1.2%) Urticaria (0.6-1.2%) Rhinorrhea (0.3-1.2%)

May enhance the adverse effects and diminish the therapeutic effect of live vaccines.